Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs.

Elagina AA, Lyashev YD, Lyashev AY, Pronyaeva TV, Chahine AR

Bulletin of experimental biology and medicine1 Mar 2020Cited by 2 (Europe PMC)

PMID32246363DOI10.1007/s10517-020-04764-2PepBankPUB-32246363

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, Semax at 200 μg/kg decreased total cholesterol.
In plain wordsIn diabetic rats, Semax lowered total cholesterol.
Peptide
Semax
Outcome
DecreaseTotal cholesterol
Study
ratn: not reported in source
streptozotocin-induced diabetes mellitus
Outcome group
Lipids · Metabolic and weight
Studied dose
200 μg/kgAs given in this study (rat).
Source sentences
Summary
Deltalicin in a dose 100 μg/kg and Semax in a dose 200 μg/kg as well as sulodexide corrected lipid metabolism disorders: the content of total cholesterol, triglycerides, LDL, index of atherogenicity decreased and HDL concentration increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Diabetes mellitus was modeled by single injection of streptozotocin (45 mg/kg) and rats with blood glucose ≥12 mmol/liter were selected for the further experiments.
Report a problemFND-3224636301
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, Semax at 200 μg/kg decreased triglycerides.
In plain wordsIn diabetic rats, Semax lowered triglycerides.
Peptide
Semax
Outcome
DecreaseTriglycerides
Study
ratn: not reported in source
streptozotocin-induced diabetes mellitus
Outcome group
Lipids · Metabolic and weight
Studied dose
200 μg/kgAs given in this study (rat).
Source sentences
Summary
Deltalicin in a dose 100 μg/kg and Semax in a dose 200 μg/kg as well as sulodexide corrected lipid metabolism disorders: the content of total cholesterol, triglycerides, LDL, index of atherogenicity decreased and HDL concentration increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Diabetes mellitus was modeled by single injection of streptozotocin (45 mg/kg) and rats with blood glucose ≥12 mmol/liter were selected for the further experiments.
Report a problemFND-3224636302
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, Semax at 200 μg/kg decreased LDL.
In plain wordsIn diabetic rats, Semax lowered LDL cholesterol.
Peptide
Semax
Outcome
DecreaseLDL cholesterol
Study
ratn: not reported in source
streptozotocin-induced diabetes mellitus
Outcome group
Lipids · Metabolic and weight
Studied dose
200 μg/kgAs given in this study (rat).
Source sentences
Summary
Deltalicin in a dose 100 μg/kg and Semax in a dose 200 μg/kg as well as sulodexide corrected lipid metabolism disorders: the content of total cholesterol, triglycerides, LDL, index of atherogenicity decreased and HDL concentration increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Diabetes mellitus was modeled by single injection of streptozotocin (45 mg/kg) and rats with blood glucose ≥12 mmol/liter were selected for the further experiments.
Report a problemFND-3224636303
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, Semax at 200 μg/kg decreased the index of atherogenicity.
In plain wordsIn diabetic rats, Semax lowered the index of atherogenicity, a blood-fat risk score.
Peptide
Semax
Outcome
DecreaseIndex of atherogenicity
Study
ratn: not reported in source
streptozotocin-induced diabetes mellitus
Outcome group
Lipids · Metabolic and weight
Studied dose
200 μg/kgAs given in this study (rat).
Source sentences
Summary
Deltalicin in a dose 100 μg/kg and Semax in a dose 200 μg/kg as well as sulodexide corrected lipid metabolism disorders: the content of total cholesterol, triglycerides, LDL, index of atherogenicity decreased and HDL concentration increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Diabetes mellitus was modeled by single injection of streptozotocin (45 mg/kg) and rats with blood glucose ≥12 mmol/liter were selected for the further experiments.
Report a problemFND-3224636304
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, Semax at 200 μg/kg increased HDL concentration.
In plain wordsIn diabetic rats, Semax raised HDL cholesterol.
Peptide
Semax
Outcome
IncreaseHDL cholesterol
Study
ratn: not reported in source
streptozotocin-induced diabetes mellitus
Outcome group
Lipids · Metabolic and weight
Studied dose
200 μg/kgAs given in this study (rat).
Source sentences
Summary
Deltalicin in a dose 100 μg/kg and Semax in a dose 200 μg/kg as well as sulodexide corrected lipid metabolism disorders: the content of total cholesterol, triglycerides, LDL, index of atherogenicity decreased and HDL concentration increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Diabetes mellitus was modeled by single injection of streptozotocin (45 mg/kg) and rats with blood glucose ≥12 mmol/liter were selected for the further experiments.
Report a problemFND-3224636305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.